Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016
Published Aug 10, 2016
102 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections
- The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- P

  
Source:
Document ID
GMDHC8352IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Influenza A Virus, H3N2 Subtype Infections Overview101
Therapeutics Development112
  Pipeline Products for Influenza A Virus, H3N2 Subtype Infections Overview111
  Pipeline Products for Influenza A Virus, H3N2 Subtype Infections Comparative Analysis121
Influenza A Virus, H3N2 Subtype Infections Therapeutics under Development by Companies132
Influenza A Virus, H3N2 Subtype Infections Therapeutics under Investigation by Universities/Institutes151
Influenza A Virus, H3N2 Subtype Infections Pipeline Products Glance163
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
Influenza A Virus, H3N2 Subtype Infections Products under Development by Companies192
Influenza A Virus, H3N2 Subtype Infections Products under Investigation by Universities/Institutes211
Influenza A Virus, H3N2 Subtype Infections Companies Involved in Therapeutics Development2219
  AbbVie Inc221
  AIMM Therapeutics B.V.231
  Aphios Corporation241
  Celltrion, Inc.251
  FluGen, Inc.261
  Glide Pharmaceutical Technologies Limited271
  ILiAD Biotechnologies, LLC281
  Inovio Pharmaceuticals, Inc.291
  Johnson &Johnson301
  Medicago Inc.311
  MedImmune, LLC321
  Mucosis B.V.331
  NanoViricides, Inc.341
  OPKO Health, Inc.351
  Sarepta Therapeutics, Inc.361
  Takeda Pharmaceutical Company Limited371
  VBI Vaccines Inc.381
  Visterra, Inc.391
  Zydus Cadila Healthcare Limited401
Influenza A Virus, H3N2 Subtype Infections Therapeutics Assessment4110
  Assessment by Monotherapy Products411
  Assessment by Combination Products421
  Assessment by Target432
  Assessment by Mechanism of Action452
  Assessment by Route of Administration472
  Assessment by Molecule Type492
Drug Profiles5146
  APP-0205 Drug Profile511
  APP-309 Drug Profile521
  Aspidasept Drug Profile531
  C-05 Drug Profile541
  CR-8020 Drug Profile551
  CR-9114 Drug Profile561
  CTP-27 Drug Profile571
  Fluad (quadrivalent) Drug Profile581
  FluGEM Drug Profile591
  Gamma-Flu Drug Profile601
  influenza [strain A/H3N2] (monovalent) vaccine Drug Profile611
  influenza [strain A/H3N2] vaccine Drug Profile621
  influenza [strain A/H3N2] vaccine Drug Profile631
  influenza [strain A/H3N2] vaccine Drug Profile641
  influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile651
  influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile661
  influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile671
  influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine Drug Profile681
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile691
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile703
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile731
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile741
  influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile751
  influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile761
  influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile771
  JNJ-872 Drug Profile782
  NEO-8877 Drug Profile801
  NVINF-1 Drug Profile814
  NVINF-2 Drug Profile853
  pertussis [strain BPZE1] vaccine Drug Profile882
  PNSIA-28 Drug Profile901
  radavirsen Drug Profile912
  REDEE FLU Drug Profile931
  Small Molecules for RSV and Influenza A Infections Drug Profile941
  VIS-410 Drug Profile952
Influenza A Virus, H3N2 Subtype Infections Dormant Projects971
Influenza A Virus, H3N2 Subtype Infections Product Development Milestones983
  Featured News &Press Releases981
    Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season981
    Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100981
    Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza992
Appendix1012
  Methodology1011
  Coverage1011
  Secondary Research1011
  Primary Research1011
  Expert Panel Validation1011
  Contact Us1011
  Disclaimer1021

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-A-Virus-H3N2-Subtype-Infections-Pipeline-Review-H2-2016-2088-16360>
  
APA:
Global Markets Direct - Market Research. (2016). Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-A-Virus-H3N2-Subtype-Infections-Pipeline-Review-H2-2016-2088-16360>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.